Boyle J, Marks P, Gibson J R
Musgrove Park Branch, Taunton and Somerset Hospital, UK.
J Int Med Res. 1989;17 Suppl 2:9B-13B.
Twelve patients with symptomatic dermographism were entered into a double-blind, crossover study. Patients received 8 mg acrivastine three times daily, 60 mg terfenadine three times daily or placebo, according to a fully randomized balanced treatment plan. Subjective clinical assessments were performed and the response to experimentally induced dermographism was assessed. Both active treatments were well tolerated and were shown to be significantly more effective than placebo in the treatment of symptomatic dermographism and in reducing the signs and symptoms of wealing induced by a dermographometer.
12名患有症状性人工荨麻疹的患者进入了一项双盲交叉研究。根据完全随机的平衡治疗方案，患者每日三次服用8毫克阿伐斯汀、每日三次服用60毫克特非那定或服用安慰剂。进行了主观临床评估，并评估了对实验性诱发人工荨麻疹的反应。两种活性治疗药物耐受性良好，且在治疗症状性人工荨麻疹以及减轻皮肤划纹器诱发的风团的体征和症状方面，均显示出比安慰剂显著更有效。
